PCM
ALNY icon

Prelude Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Prelude Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-928
Closed -$369K – 1196
2025
Q4 		$369K Buy
+928
New +$411K 0.03% 682
2025
Q2 		– Sell
-5,408
Closed -$1.46M – 993
2025
Q1 		$1.46M Buy
5,408
+595
+12% +$153K 0.11% 211
2024
Q4 		$1.13M Sell
4,813
-20
-0.4% -$5.26K 0.07% 352
2024
Q3 		$1.33M Sell
4,833
-100
-2% -$26K 0.08% 310
2024
Q2 		$1.2M Sell
4,933
-1,998
-29% -$315K 0.08% 283
2024
Q1 		$1.04M Buy
6,931
+5,275
+319% +$880K 0.05% 394
2023
Q4 		$317K Buy
+1,656
New +$282K 0.02% 711
2023
Q2 		– Sell
-1,788
Closed -$358K – 1103
2023
Q1 		$358K Buy
+1,788
New +$376K 0.02% 583
2021
Q4 		– Sell
-4,755
Closed -$898K – 1969
2021
Q3 		$898K Sell
4,755
-3,209
-40% -$602K 0.02% 613
2021
Q2 		$1.35M Sell
7,964
-6,216
-44% -$910K 0.04% 458
2021
Q1 		$2M Buy
+14,180
New +$2.13M 0.05% 337
2020
Q4 		– Sell
-1,230
Closed -$179K – 1252
2020
Q3 		$179K Sell
1,230
-836
-40% -$119K 0.01% 717
2020
Q2 		$306K Buy
+2,066
New +$279K 0.02% 616
2016
Q2 		– Sell
-947
Closed -$59K – 1560
2016
Q1 		$59K Sell
947
-8,020
-89% -$533K 0.01% 935
2015
Q4 		$844K Buy
8,967
+1,897
+27% +$176K 0.13% 183
2015
Q3 		$568K Sell
7,070
-682
-9% -$75.8K 0.08% 255
2015
Q2 		$929K Sell
7,752
-370
-5% -$44.2K 0.13% 188
2015
Q1 		$848K Buy
8,122
+4,855
+149% +$492K 0.12% 216
2014
Q4 		$317K Buy
+3,267
New +$303K 0.05% 481
2014
Q1 		– Sell
-6,085
Closed -$391K – 1835
2013
Q4 		$391K Hold
6,085
– – 0.06% 434
2013
Q3 		$390K Sell
6,085
-16,161
-73% -$806K 0.06% 357
2013
Q2 		$690K Buy
+22,246
New +$592K 0.15% 177

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prelude Capital Management's ALNY Position: Q1 2026 in Review

Prelude Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 928 shares — an estimated $369K sold.

Prelude Capital Management first reported a position in ALNY in Q2 2013 and held it in 22 quarters. The position peaked at $2M in Q1 2021. 791 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Prelude Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 928 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $369K.
  • Prelude Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • Prelude Capital Management's Alnylam Pharmaceuticals position peaked at $2M in Q1 2021.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.